Advertisement

Soluble Fas Ligand Levels in Cerebrospinal Fluid in Neuro-Behçet’s Disease

  • E. Aoyama-Hayashi
  • T. Matsuda
  • N. Ohya
  • C. Tanaka
  • M. kongozi
  • C. Kamo
  • M. Hotta
  • H. Ikejima
  • M. Shiraishi
  • Y. Mizushima
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 528)

Keywords

Multiple Sclerosis Cerebrospinal Fluid Rheumatic Disease Active Stage Central Nervous System Involvement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Suda, T., Takahashi, T., Golstein, P., et al., 1993, Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169–1178.CrossRefPubMedGoogle Scholar
  2. 2.
    Nozawa, K., Kayagaki, N., Takano, Y., et al., 1997, Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum. 40: 1126–1129.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • E. Aoyama-Hayashi
    • 1
  • T. Matsuda
    • 1
  • N. Ohya
    • 1
  • C. Tanaka
    • 1
  • M. kongozi
    • 1
  • C. Kamo
    • 1
  • M. Hotta
    • 1
  • H. Ikejima
    • 1
  • M. Shiraishi
    • 1
  • Y. Mizushima
    • 1
  1. 1.Department of Internal Medicine, Institute of Medical ScienceSt. Marianna University School of MedicineKawasakiJapan

Personalised recommendations